Join leading clinicians and experts from Prostate Cancer UK, Neuroendocrine Cancer UK and more in launching new policy recommendations and a situation analysis report to improve readiness for radioligand therapy in the UK
Radioligand therapy is a highly targeted cancer therapy. It is currently approved by the Medicines and Healthcare products Regulatory Agency as a treatment for certain types of neuroendocrine neoplasms and lymphoma, and is under investigation for metastatic castration-resistant prostate cancer and many other cancers.
With new applications of radioligand therapy on the horizon, we must consider how to reduce existing variation in access and also proactively plan for wider future use.
The Policy Action Blueprint for Radioligand Therapy in the UK and accompanying Situation Analysis Report provide an overview of current integration of radioland therapy in the UK and propose policy recommendations to improve integration and achieve health system readiness for the therapy.
This event will explore how to drive proactive policymaking for radioligand therapy and build a ready system for integrating new targeted cancer therapies in the future.
Dr Martin Rolles, Radiotherapy Lead, Wales Cancer Network
Dr John Buscombe, Former President British Nuclear Medicine Society, Locum Consultant Barts Health NHS Trust
Ms Nikie Jervis, Patient Support Manager and Information Nurse Specialist, Neuroendocrine Cancer UK
Ms Karen Stalbow, Head of Policy, Knowledge and Impact, Prostate Cancer UK
Moderator: Dr Suzanne Wait, Managing Director, The Health Policy Partnership
The materials launched at this event have been developed by HPP with guidance from a UK Expert Advisory Group. The group has had full editorial control over all outputs. All project outputs are non-promotional, consensus driven and evidence-based. The project is supported with funding from Advanced Accelerator Applications, a Novartis Company, with additional support from Nordic Nanovector.